ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) shares reached a new 52-week low on Monday . The stock traded as low as $0.21 and last traded at $0.24, with a volume of 11300 shares trading hands. The stock had previously closed at $0.25.
EPIX has been the topic of several recent analyst reports. Zacks Investment Research raised ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Monday, September 11th. Bloom Burton lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $4.75.
The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.